Ciphergen Names Vice President of Diagnostic Operations
March 08 2004 - 9:00AM
PR Newswire (US)
Ciphergen Names Vice President of Diagnostic Operations FREMONT,
Calif., March 8 /PRNewswire-FirstCall/ -- Ciphergen Biosystems,
Inc. announced today that William Sullivan has joined Ciphergen as
Vice President, Diagnostics Operations, in its newlyformed
Diagnostics Division. In his new position, Mr. Sullivan will manage
general operations in support of a major clinical diagnostics
business initiative by the company to develop and commercialize
Protein Molecular Diagnostics, based on the ProteinChip(R)
platform. "We are pleased that Bill is joining Ciphergen to provide
critical product development and operational expertise as we
implement our Protein Molecular Diagnostics commercialization
effort," stated Gail S. Page, President of Ciphergen's Diagnostics
Division. "He will apply seasoned management skills to our efforts
to translate our biomarker discoveries into commercial clinical
diagnostics." Bill has spent over 25 years in the diagnostics
industry, covering all aspects of clinical laboratory operations
and diagnostic manufacturing, including quality systems, product
development, technical transfer, customer support and operations
management. Prior to joining Ciphergen, he was Vice President of
Diagnostic Manufacturing at Visible Genetics, Inc. as they brought
the first FDA cleared HIV genotyping product to the market. At
Nichols Institute Diagnostics (a division of Quest Diagnostics) he
served as Vice President of Operations with major responsibilities
for reagent and instrument manufacture, field service and
facilities management. Previously he served in management roles at
Laboratory Corporation of America and its predecessor Roche
Biomedical Laboratories, Geometric Data Company (a subsidiary of
SmithKline Beckman) and GenTrak, Inc. Bill spent ten years in
technical and management positions in the Department of Pathology
and Laboratory Medicine at the Hospital of the University of
Pennsylvania. He graduated with an AB degree from the College of
the Holy Cross and subsequently attended graduate school at the
University of Pennsylvania. He holds certification as a Specialist
in Immunology from the American Society for Clinical Pathology.
Beginning in 2000, Ciphergen established the first of a series of
Biomarker Discovery Centers(R) and established a major
collaboration with the Johns Hopkins University School of Medicine
with the intention of employing Ciphergen technology to discover
biomarkers and develop assays based on panels of biomarkers which
might have greater predictive power than single marker tests. While
Ciphergen is perhaps best noted for its diagnostic efforts in the
early detection in cancer, the company also has active discovery
programs underway in neurology, cardiovascular and infectious
disease, focused on a variety of clinical questions including
disease treatment response, monitoring, classification and
prognosis. About Ciphergen Ciphergen's Diagnostics Division is
dedicated to the discovery of protein biomarkers and panels of
biomarkersand their development into protein molecular diagnostic
tests that improve patient care; and to providing collaborative
R&D services through its Biomarker Discovery Center(R)
laboratories for biomarker discovery for new diagnostic tests as
well as pharmacoproteomic services for improved drug toxicology,
efficacy and theranostic assays. Ciphergen's Biosystems Division
develops, manufactures and markets a family of ProteinChip(R)
Systems and services for clinical, research, and process proteomics
applications, as well as a broad range of bioseparations media for
protein purification and large scale production. ProteinChip
Systems enable protein discovery, characterization, identification
and assay development to provide researchers with predictive,
multi-marker assay capabilities and a better understanding of
biological function at the protein level. Additional information
about Ciphergen can be found at http://www.ciphergen.com/. Safe
Harbor Statement Note Regarding Forward-Looking Statements:For
purposes of the Private Securities Litigation Reform Act of 1995
(the "Act"), Ciphergen disclaims any intent or obligation to update
these forward-looking statements, and claims the protection of the
Safe Harbor for forward-looking statements contained in the Act.
Examples of such forward-looking statements include statements
regarding the use of ProteinChip technology to discover useful
protein biomarkers, develop and commercialize clinical diagnostics
that improve patient care, the ability to provide services that
lead to improved toxicology assays and diagnostic assays, and
statements regarding our Diagnostics Division. Actual results may
differ materially from those projected in such forward-looking
statements due to various factors, including the ProteinChip
technology's ability to validate and/or develop protein biomarkers
as diagnostic or toxicology assays, and the Company's ability to
successfully commercialize such tests. Investors should consult
Ciphergen's filings with the Securities and Exchange Commission,
including its Form 10-Q dated November 14, 2003, for further
information regarding these and the other risks of the Company's
business. Ciphergen, ProteinChip, BioSepra and Biomarker Discovery
Center are registered trademarks of Ciphergen Biosystems, Inc.
DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers,
Investor Relations of Ciphergen Biosystems, Inc., +1-510-505-2297
Web site: http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From May 2024 to Jun 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2023 to Jun 2024